What did the HARBOR AMD study conclude about the monthly injection doses of 0.5 mg and 2 mg?

The HARBOR AMD study concluded that both the 0.5 mg and 2 mg monthly injection doses of the test drug provided similar results in terms of efficacy for the treatment of neovascular age-related macular degeneration (AMD). This finding is significant as it indicates that increasing the dose does not lead to a proportionate increase in effectiveness, and both dosages can be considered adequate for managing the condition. This essentially means that patients and clinicians have the flexibility to choose a dosing regimen that may be more comfortable or suitable for the patient's needs, without compromising treatment outcomes. The results suggest a potential for minimizing side effects and treatment burden, as the lower dose remains effective in achieving comparable visual outcomes.